PE20070192A1 - Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina - Google Patents

Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina

Info

Publication number
PE20070192A1
PE20070192A1 PE2006000833A PE2006000833A PE20070192A1 PE 20070192 A1 PE20070192 A1 PE 20070192A1 PE 2006000833 A PE2006000833 A PE 2006000833A PE 2006000833 A PE2006000833 A PE 2006000833A PE 20070192 A1 PE20070192 A1 PE 20070192A1
Authority
PE
Peru
Prior art keywords
succinate
demethylvenlafaxine
dosage forms
release dosage
available oral
Prior art date
Application number
PE2006000833A
Other languages
English (en)
Spanish (es)
Inventor
Syed Shah
Mahdi B Fawzi
Christopher Richard Dioro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20070192A1 publication Critical patent/PE20070192A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2006000833A 2005-07-15 2006-07-13 Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina PE20070192A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69962305P 2005-07-15 2005-07-15

Publications (1)

Publication Number Publication Date
PE20070192A1 true PE20070192A1 (es) 2007-03-16

Family

ID=37669348

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000833A PE20070192A1 (es) 2005-07-15 2006-07-13 Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina

Country Status (20)

Country Link
US (1) US20070014859A1 (https=)
EP (1) EP1904040A2 (https=)
JP (1) JP2009501233A (https=)
KR (1) KR20080025405A (https=)
CN (1) CN101247791A (https=)
AR (1) AR054833A1 (https=)
AU (1) AU2006270315A1 (https=)
BR (1) BRPI0613484A2 (https=)
CA (1) CA2612960A1 (https=)
CR (1) CR9626A (https=)
EC (1) ECSP088106A (https=)
GT (1) GT200600307A (https=)
IL (1) IL188313A0 (https=)
MX (1) MX2008000666A (https=)
NO (1) NO20080088L (https=)
PE (1) PE20070192A1 (https=)
RU (1) RU2007148195A (https=)
SV (1) SV2008002612A (https=)
TW (1) TW200740427A (https=)
WO (1) WO2007011619A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
DE602006010343D1 (de) * 2005-03-31 2009-12-24 Wyeth Corp Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
US20080175873A1 (en) * 2005-06-02 2008-07-24 Biovail Laboratories International S.R.L. Modified release composition of at least one form of venlafaxine
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2629609A1 (en) * 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
TR200909798T1 (tr) * 2007-07-12 2010-05-21 Dr. Reddy's Laboratories Ltd. O-desmetilvenlafaksin.
CA2702664A1 (en) * 2007-10-16 2009-04-23 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0722303A2 (pt) * 2007-12-10 2014-04-22 Wyeth Llc O-desmatil-venlafaxina para tratar transtorno depressivo maior
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN101716168B (zh) * 2008-10-09 2014-09-17 北京德众万全医药科技有限公司 一种含有去甲文拉法新的盐的药物组合物及其制备方法
EP2191822A1 (en) 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
CA2780332C (en) 2009-11-09 2018-01-30 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
MX2012010659A (es) 2010-03-31 2013-03-05 Wockhardt Ltd Composicion farmaceutica de liberacion modificada que comprende desvenlafaxina o sus sales.
CN102085197B (zh) * 2010-12-14 2013-08-14 北京万生药业有限责任公司 一种文拉法辛缓释制剂及其制备方法
KR20140030156A (ko) 2011-04-12 2014-03-11 루핀 리미티드 방출-조절되는 데스벤라팍신 약학 조성물
CN111008356B (zh) * 2019-11-13 2023-06-16 成都理工大学 一种基于WTSVD算法扣除背景的γ能谱集分析方法
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
ES2277030T3 (es) * 2003-05-02 2007-07-01 Dexcel Ltd. Formulacion en comprimidos de venlafaxina de liberacion prolongada.
AU2005212166A1 (en) * 2004-02-06 2005-08-25 Wyeth Multiparticulate O-desmethylvenlafaxine salts and uses thereof
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology

Also Published As

Publication number Publication date
WO2007011619A2 (en) 2007-01-25
MX2008000666A (es) 2008-03-13
US20070014859A1 (en) 2007-01-18
SV2008002612A (es) 2008-08-29
EP1904040A2 (en) 2008-04-02
BRPI0613484A2 (pt) 2016-11-16
CR9626A (es) 2008-04-10
KR20080025405A (ko) 2008-03-20
NO20080088L (no) 2008-04-02
CA2612960A1 (en) 2007-01-25
GT200600307A (es) 2008-04-24
WO2007011619A3 (en) 2007-06-21
JP2009501233A (ja) 2009-01-15
RU2007148195A (ru) 2009-08-20
CN101247791A (zh) 2008-08-20
ECSP088106A (es) 2008-02-20
IL188313A0 (en) 2008-04-13
TW200740427A (en) 2007-11-01
AU2006270315A1 (en) 2007-01-25
AR054833A1 (es) 2007-07-18

Similar Documents

Publication Publication Date Title
PE20070192A1 (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
PE20120476A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
PE20091971A1 (es) Formulaciones orales de analogos de citidina y metodos de uso de los mismos
NZ594022A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
PE20070458A1 (es) Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
TW200626558A (en) Indazolone derivatives
HN2006020928A (es) "composiciones de tanaproget que contienen etinil estradiol"
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
NO20085414L (no) Farmasoytiske preparater for vedvarende frigivelse av fenylefrin
SG152257A1 (en) Topical preparation containing ambroxol
CR10289A (es) "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)
AR054806A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
GT200400134A (es) Sistemas emulsionantes que contienen derivados de azetidina
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina
WO2003105811A8 (en) PROGRESSIVE RELEASE COMPOSITIONS AND METHOD OF USE
DE60312642D1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
UA40964U (uk) Лікарський препарат у формі таблеток
PE20050188A1 (es) Monohidrato de 4-ciclopentilresorcinol como agente de despigmentacion

Legal Events

Date Code Title Description
FX Voluntary withdrawal